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During the early phase of replication,HIV reverse tran-
scribes its RNA and crosses the nuclear envelope
whileescapinghostantiviraldefenses. Thehost factor
Cyclophilin A (CypA) is essential for these steps and
binds theHIVcapsid; however, themechanismunder-
lying this effect remains elusive. Here, we identify
related capsid mutants in HIV-1, HIV-2, and SIVmac
that are restricted by CypA. This antiviral restriction
of mutated viruses is conserved across species and
prevents nuclear import of the viral cDNA. Impor-
tantly, the inner nuclear envelope protein SUN2 is
required for the antiviral activity of CypA. We show
that wild-type HIV exploits SUN2 in primary CD4+
T cells as an essential host factor that is required for
the positive effects of CypA on reverse transcription
and infection. Altogether, these results establish
essential CypA-dependent functions of SUN2 in HIV
infection at the nuclear envelope.INTRODUCTION
HIV replication requires the successful orchestration of reverse
transcription, nuclear entry, and integration while avoiding
various antiviral factors and innate immune sensors during early
steps of infection (Malim and Bieniasz, 2012). Recognition
of HIV by innate immune sensors induces the production of
type I interferons and consequently interferon-stimulated genes
(ISGs), some of which possess direct antiviral activity against
HIV replication (Schoggins et al., 2011). Along with ISGs, cells
are also equipped with intrinsic antiviral factors, including re-
striction factors that constitutively protect the cell from infection
(Bieniasz, 2004). Cyclophilin A (CypA), a host peptidylprolylThis is an open access article under the CC BY-Nisomerase, was the first host factor shown to bind the HIV-1
capsid protein and to be required for the early steps of infection
(Luban et al., 1993). Since the capsid core efficiently protects
the genome of pathogenic HIV-1, engages essential host-
derived replication factors, and enables evasion of antiviral fac-
tors and innate immune sensors, its interaction with CypA is of
particular interest (Campbell and Hope, 2015). To date, CypA
has not been associated with specific cellular pathways in
human cells, and the nature of cellular factor(s) required for
the effects of CypA on HIV-1 infection has remained elusive
(Hilditch and Towers, 2014).
In primary CD4+ target cells, HIV depends on CypA for
maximal replication (De Iaco and Luban, 2014; Franke et al.,
1994; Saini and Potash, 2006; Schaller et al., 2011; Yoo et al.,
1997). Use of the CypA inhibitor Cyclosporin A (CsA) demon-
strated that optimal reverse transcription of HIV-1 (Braaten
et al., 1996) and viral nuclear import (De Iaco and Luban, 2014)
requires CypA in many cell lines, consistent with the ability of
lentiviruses to infect non-dividing cells and with the presence
of a conserved CypA-binding loop in their capsid (Goldstone
et al., 2010; Lin and Emerman, 2006; Yamashita and Emerman,
2004). CypA also influences HIV-1 integration sites (Schaller
et al., 2011) and the evasion of cytosolic innate sensors in mono-
cyte-derived macrophages (Rasaiyaah et al., 2013). Unlike
HIV-1, HIV-2 and simian immunodeficiency virus (SIV)mac repli-
cation is modestly affected by inhibition of CypA in cell lines
(Billich et al., 1995; Thali et al., 1994). Accordingly, HIV-1 capsid
binds CypA with an affinity in the micromolar range, while HIV-2
and the related SIVmac capsids bind CypA with a much lower
affinity (Price et al., 2009; Schaller et al., 2011). In several cell
lines such as HeLa, HIV-1 does not depend on CypA (Sokolskaja
et al., 2004; Thali et al., 1994), and heterokaryon experiments
suggest instead that CypA controls a dominant restrictionmech-
anism specific to HeLa cells and to capsid mutants A92E and
G94D (Song and Aiken, 2007). Mutations conferring a restric-
tion phenotype that would be both associated with CypA andCell Reports 15, 879–892, April 26, 2016 ª2016 The Authors 879
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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conserved across cell types in single-cycle virus infection assays
have remained elusive.
Additional host factors that regulate the early steps of
HIV-1 replication are also associated with capsid. For instance,
CPSF6, RANBP2 (NUP358), NUP153, and Rhesus TRIM5a all
bind to the viral capsid (Di Nunzio et al., 2012; Ganser-Pornillos
et al., 2011; Lee et al., 2010; Matreyek and Engelman, 2011;
Meehan et al., 2014; Price et al., 2012; Schaller et al., 2011;
Stremlau et al., 2004). TNPO3 is also required for HIV-1 infection
and this requirement maps genetically in part to the viral capsid
(Brass et al., 2008; Krishnan et al., 2010). Interestingly, the resis-
tance factor MX2 inhibits HIV-1 infection after reverse transcrip-
tion, and this maps to the interaction between the viral capsid
and CypA (Goujon et al., 2013; Kane et al., 2013; Liu et al.,
2013). The understanding of the orchestration of the early steps
of HIV-1 infection by these factors, particularly at the step
of nuclear entry of the viral pre-integration complex, remains
incomplete (Gaudin et al., 2013). Mutations in the viral capsid
that alter CypA binding alsomodulate the effects of these factors
on infection, leading to the notion that CypA binding to capsid
influences interactions (genetic or biochemical) with these fac-
tors (Sokolskaja and Luban, 2006). However, no essential host
factor is known to be required for the effects of CypA on HIV-1
infection.
CypA binds to a characteristic proline-containing loop that is
present in lentiviruses but absent from other retroviruses (Gold-
stone et al., 2010; Lin and Emerman, 2006) and affects the isom-
erization of proline 90 in HIV-1 capsid (Bosco et al., 2002). We
previously described chimeric mutants of HIV-1 and HIV-2,
corresponding to naturally occurring amino acids, with an
increased affinity for CypA: P86HA in HIV-2 (short HIVac-2;
HIV CypA affinity-enhanced capsid) and V86I-IAP91LPA-M96L
in HIV-1 (short HIVac-1) (Lahaye et al., 2013). In monocyte-
derived dendritic cells (MDDCs), a physiologically relevant CD4+
target cell derived from primary blood monocytes, HIVac-1 and
HIVac-2 promote innate sensing of the viral cDNAby the cytosolic
DNA sensor cyclic GMP-AMP synthase (cGAS) before nuclear
import (Lahaye et al., 2013). This response requires abrogation
of SAMHD1 using Vpx present in HIV-2/SIVmac (Hrecka et al.,Figure 1. CypA Is Required for a Restriction of HIV-1 and HIV-2 Capsid
(A) GFP expression in MDDCs 48 hr after infection with HIV-1 WT, HIVac-1, HIV-
presence SIVmac251 VLPs (Vpx) and treated or not with CsA (2 mM) (n = 5; repr
(B) GFP expression in MDDCs (n = 10 except HIV-1 viruses n = 8, paired t test, ***
volume is indicated.
(C) Infectious titer of HIV-1 WT, HIVac-1, HIV-2 WT, and HIVac-2 on GHOST cel
absence of CsA (2 mM) (n = 12, paired t test on log-transformed data, *p < 0.05,
(D) GFP expression inMDDCs 48 hr after infection with HIV-1WT, HIVac-1, HIV-2
2 mM of CBS1 or CsA (n = 2, except HIV-1 viruses n = 1; open symbols, individu
(E) Western blot analysis of CypA and actin expression in THP-1 cells transduce
(F) GFP expression in PMA-differentiated THP-1 cells transduced with a control
HIV-1WT, HIVac-1, HIV-2 WT, and HIVac-2 (n = 6, paired t test, ***p < 0.001, ****
(G) Western blot analysis of CypA and actin expression (day 4). MDDCs were tra
vector.
(H) MDDCs as in (G) were infected at day 4 with HIVac-2. Proportion of GFP-pos
mean). Virus inoculum volume is indicated.
(I) MDDCs were transduced at day 0 with a single shRNA vector against CypA or c
ntCypA-encoding vector, and infected at day 4 with HIVac-2 (n = 5). GFP and ta
rescue of the restriction by the expression of the ntCypA in absence of the endo
See also Figure S1.2011; Laguette et al., 2011; Manel et al., 2010). In addition, these
mutants show a striking defect in infection of MDDCs, down-
stream of the SAMHD1 restriction (Lahaye et al., 2013). Neutral-
izing type I interferon (IFN) does not rescue infection by HIVac-2,
suggesting that the inhibition is not secondary to the induction
of an antiviral innate immune state. HIVac-2 gives rise to normal
levels of late reverse transcription (late RT) products, but reduced
levels of 2-LTR circles and integrated viral DNA, as compared
to HIV-2, suggesting a restriction before nuclear import. We sur-
mised that the increased affinity of HIVac-2 for CypA rendered
the virus intrinsically susceptible to antiviral restriction mediated
by CypA at the level of nuclear import. Normally, wild-type (WT)
HIV would avoid such CypA-mediated resistance, a typical char-
acteristic of restriction factors (Malim and Bieniasz, 2012). This
observation raised the possibility that the underlying restriction
mechanism could shed light on the long-sought host factors
implicated in the positive effects of CypA in HIV-1 infection.
RESULTS
CypA Is Required for Restriction of HIVac Capsid
MDDCs were susceptible to infection by HIV-1 with Vpx, but not
to HIVac-2 infection (Figure S1A). We examined whether the
resistance to HIVac-2 infection was intrinsic to the virus. Upon
combined infection with the two viruses, when HIVac-2 was pre-
sent and activated an innate immune response in MDDCs as
shown by CD86 induction, cells remained susceptible to HIV-1
with Vpx (Figure S1A). Thus, the resistance to HIVac-2 infection
is unlikely due to the induction of an antiviral state but appears to
be intrinsically linked to the capsid.
In order to examine the role of CypA in HIV resistance, we
treated MDDCs with CsA at the time of infection. CsA modestly
increased HIV-2 infectivity and decreased HIV-1 infectivity,
consistent with previous reports (Manel et al., 2010; Virgen
et al., 2008) (Figures 1A, 1B, S1B, and S1C). Strikingly, in the
case of infection of DCs with HIVac-1 and HIVac-2, the presence
of CsA restored infectivity (Figures 1A, 1B, S1B, and S1C). This
indicated that the HIVac mutations enabled a CypA-mediated
restriction of infection.Mutants
2 WT, and HIVac-2 encoding GFP in Nef and pseudotyped with VSV-G in the
esentative data for one donor are shown).
*p < 0.0001; ns, not statistically significant; bar indicates mean). Virus inoculum
ls normalized to reverse transcriptase titer of the inoculum, in the presence or
***p < 0.001, ****p < 0.0001; ns, not statistically significant; bar, mean ± SEM).
WT, and HIVac-2 in the presence SIVmac251 VLPs (Vpx) and treated or not with
al donors; bar, mean). Virus inoculum volume is indicated.
d with a control shRNA against LacZ or shRNA #3 against of CypA.
shRNA against LacZ or shRNA #3 against of CypA, 48 hr after infection with
p < 0.0001, bar indicates mean). Virus inoculum volume is indicated.
nsduced at day 0 with three shRNA vectors against CypA or a shRNA control
itive cells after 48 hr of infection (n = 4, paired t test, **p < 0.01, line indicates
ontrol vector, together with a tagRFP-encoding vector or a tagRFP-2A-FLAG-
gRFP expression in a representative donor is shown. Red arrows indicate the
genous CypA.
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Figure 2. CypA Induces a Direct Antiviral Resistance against a Family of Capsid Mutants in HIV and SIV that Is Conserved in Human and
Macaque Cells
(A) 4,132 sequences of HIV-1 capsid available in the Los Alamos National Laboratory database were aligned and six unique pairs of amino acids preceding
Glycine 89-Proline 90 were extracted. A histogram of the number of sequences for this pair of amino acids at this position is shown.
(B) Alignment of the CypA-binding loops of HIV-1 WT, HIV-2 WT, HIVac-2 capsids, and the six pairs of amino acids (as in Figure 4A) in HIV-2 ROD9 instead of
Proline 86.
(legend continued on next page)
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Next, we reasoned that, if the restriction of HIVac viruses was
not a consequence of the induction of an antiviral state in
immune cells, then it must be conserved. HIVac-1 and HIVac-2
titers were decreased compared to their WT counterparts
following infection of immune-related THP-1 cells and non-im-
mune GHOST cells (Figures 1C, S1D, and S1E). CsA restored
infection of HIVac-1 and HIVac-2 to levels comparable with
those of the WT viruses. CsA, an immunosuppressive com-
pound, also targets proteins other than CypA. To confirm the
role of CypA, we used a non-immunosuppressive CypA inhibitor,
CBS1. CBS1 also rescued infectivity of HIVac-1 and HIVac-2
(Figure 1D). Knockdown of CypA expression in MDDCs and
THP-1 using short hairpin RNA (shRNA)-coding lentivectors
also restored infectivity of HIVac-2 (Figures 1E–1H). Expression
of a non-targetable CypA protein together with the shRNA re-
verted the inhibition of HIVac-2 infection (Figures 1I and S1F–
S1I). To genetically confirm the role of CypA, we used PPIA/
Jurkat cells that are genetically defective for CypA expression
(Braaten and Luban, 2001). As was the case for MDDCs and
GHOST cells, infection of WT Jurkat cells by HIVac-2 was in-
hibited, and addition of CsA rescued infectivity (Figures S1J
and S1K). In contrast, infectivity of HIVac-2 was similar to
HIV-2 in PPIA/ Jurkat cells, and CsA had no further effect
on infectivity. Thus, CypA is essential to restrict HIVac-1 and
HIVac-2 capsid mutants.
CypA Mediates a Conserved Restriction of a Family of
Lentiviral Capsid Mutants
Next, we examined whether the CypA restriction was limited to a
specific HIVac capsid sequence or whether it could be extended
to a general family of lentiviral capsid mutants. The distinctive
feature of HIVac-2 is the rational exchange of Proline 86 with a
corresponding pair of naturally occurring amino acids Histi-
dine-Alanine in HIV-1 NL4-3, in order to restore a CypA-binding
loop that would presumably fit the catalytic site of CypA more
closely (Lahaye et al., 2013). We examined an alignment of
4,132 sequences of HIV-1 capsid available at the time in the
Los Alamos National Laboratory database and extracted all the
existing pairs of amino acids preceding Glycine 89-Proline 90.
We identified six additional amino acid pairs and introduced
them into HIV-2 ROD9 (Figures 2A and 2B). In accordance with
HIVac-2, these six mutants encapsidated higher amounts of
CypA protein in the viral particles (between 20- and 50-fold
more, Figure S2A), consistent with an increased affinity of these
mutated capsids for CypA (Lahaye et al., 2013). On GHOST cells
and MDDCs, infectivity was consistently low and rescued
by CsA, except for one mutant P86AA (Figures 2C and S2B).
HIV-2 is closely related to SIVmac, but their CypA-binding loops
differ. To examine whether the CypA restriction was applicable
to primate lentiviruses other than HIV, we generated a mutant(C) GFP expression in MDDCs 48 hr after infection with HIV-2 WT, HIVac-2, and ad
(n = 4, paired t test, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not statistically s
(D) Alignment of the CypA-binding loops of HIV-1 WT, HIVac-1, HIV-2 WT, HIVac
(E) GFP expression in macaqueMDDCs 48 hr after infection with SIVmac239 and S
VSV-G and treated or not with CsA (2 mM) or raltegravir (RAL) (20 mM) (n = 4; rep
(F) GFP expression as in Figure 2E (n = 4, paired t test, **p < 0.01, ****p < 0.0001;
See also Figure S2.of SIVmac239 encoding for the CypA-binding loop of HIVac-2,
resulting in virus SIVmac239 QPAPQQ85IHAGPLPA (Figure
2D). We also generated macaque monocyte-derived dendritic
cells (O’Doherty et al., 1997) (Figure S2C). Macaque MDDCs
were readily infected with VSV-G pseudotyped GFP-encoding
SIVmac239 (Figures 2E and 2F). Infection was inhibited by Ralte-
gravir, confirming that GFPwas expressed from integrated virus.
CsA did not alter SIVmac239 infection. In contrast, infectivity of
SIVmac239 QPAPQQ85IHAGPLPA was inhibited in macaque
MDDCs, and CsA treatment restored GFP expression. Thus,
CypA restriction of lentiviral infection is conserved in macaque
cells and affects a broad family of capsid mutants.
Second-Site Mutations in HIVac Capsid Rescue the
CypA Restriction
To determine whether CypA was sufficient for restriction, we
explored the phenotype of second-site mutations in the capsid
mutants. The capsid mutant HIV-1 N74D, but not HIV-1 WT,
has been previously shown to be sensitive to CsA in HeLa cells
(Ambrose et al., 2012; Yang and Aiken, 2007). This suggested
that N74 might influence the restriction mediated by CypA
on HIVac-1 and HIVac-2. Strikingly, the infectivity of HIVac-1
N74D and HIVac-2 N73D was largely restored and was insensi-
tive to CsA in HeLa cells, GHOST cells, andMDDCs (Figures 3A–
3D, S3A, and S3B). Importantly, the second-site mutation did not
abrogate the increase in CypA recruitment to the HIVac-2 N73D
capsid (Figures 3E and S3C). Thus, N74D/N73D constitute sec-
ond-site mutations in capsids that specifically escape the direct
antiviral effect of CypA, suggesting that additional host factors
are implicated in the restriction.
Role of Known Capsid-Associated Factors in the
Restriction
Next, we examined whether host factors that bind the lentiviral
capsid or whose activity genetically maps to the capsid would
be necessary for the restriction. We focused on THP-1 cells,
because GHOST cells are already multi-resistant to antibiotic
selection, and sufficient knockdown was difficult to achieve for
several host factors in MDDCs (data not shown). We knocked
down MX2, TNPO3, CPSF6, NUP153, RANBP2, and TRIM5
and tested whether this would rescue infection by HIVac-1
or HIVac-2. Knockdowns were confirmed by western blot for
MX2, CPSF6, and TNPO3 (Figure S4A), and by qPCR for
RANBP2, NUP153, and TRIM5 (Figure S4B). Depletion of
TNPO3, CPSF6, NUP153, RANBP2, and MX2 reduced HIV-1
and HIV-2 infections, with TNPO3 depletion having the strongest
inhibitory effect (Figures 4A andS4C). Depletion of TRIM5 did not
affect HIV-1 or HIV-2 infection but rescued infection by a N-MLV
retroviral vector (Bock et al., 2000) (Figures 4B and S4D). These
effects validated the functional impact of all knockdowns on HIVditional HIV-2 mutants (as indicated) in the presence or absence of CsA (2 mM)
ignificant; bar, mean). Virus inoculum volume is indicated.
-2, SIVmac239, and SIVmac239 QPAPQQ85IHAGPLPA.
IVmac239 QPAPQQ85IHAGPLPA encoding GFP in Nef and pseudotypedwith
resentative data for one donor are shown).
ns, not statistically significant; bar, mean). Virus inoculum volume is indicated.
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Figure 3. Second-Site Mutations in HIVac Capsid Rescue the CypA Restriction
(A) Alignment of the capsids of HIV-1 WT, HIVac-1, HIVac-1 N74D, HIV-2 WT, HIVac-2, and HIVac-2 N73D. The CypA-binding loop and its N-terminally adjacent
domain are shown.
(B) Infectious titer of indicated viruses onGHOST cells normalized to reverse transcriptase titer of the inoculum, in the presence or absence of CsA (2 mM) (n = 4 for
HIV-1 viruses and n = 3 for HIV-2 viruses, paired t test on log-transformed data, **p < 0.01; bar, mean ± SEM).
(C) GFP expression in MDDCs 48 hr after infection with HIVac-2 and HIVac-2 N73D viruses treated or not with CsA (2 mM) (n = 6, representative data for one donor
are shown).
(D) Quantification of GFP expression as in (C) (n = 6 except HIV-1 viruses n = 4, paired t test, ***p < 0.001, ns, not statistically significant; bar, mean). Virus inoculum
volume is indicated.
(E) Western blot analysis of Gag/Ca, CypA in Vpx in viral particles as indicated.
See also Figure S3.infection in THP-1 cells. However, there was no rescue of
HIVac-1 or HIVac-2 infection in any of these cases.
CypA Restricts HIVac Capsids at Nuclear Import
Next, we examined at which stage CypA inhibits infection with
HIVac-1 and HIVac-2. In MDDCs, the levels of late reverse tran-
scription products were similar between WT HIV and HIVac vi-
ruses (Figures 5A and S5A). However, the levels of 2LTR circles
and integrated DNA were reduced for HIVac. Addition of CsA
during infection with HIVac-2 restored the formation of 2LTR cir-
cles and integrated DNA (Figure 5A). Thus, HIVac viruses prog-
ress normally through reverse transcription and are specifically
restricted by CypA at the level of nuclear import.
SUN2 Is Required for the CypA Restriction of HIVac
Capsids
The CypA-mediated restriction at nuclear import suggested to
us that a nuclear envelope protein could be involved. We were
intrigued by finding that SUN2 (UNC84B), an inner nuclear mem-
brane protein and member of the Linker of Nucleoskeleton and884 Cell Reports 15, 879–892, April 26, 2016Cytoskeleton (LINC) complex, inhibits HIV infection when it
is artificially overexpressed (Schoggins et al., 2011). While
SUN2 was suggested to be an IFN-stimulated gene (Schoggins
et al., 2011), we found that it is expressed constitutively in
THP-1 cells and MDDCs and it is not induced by type I IFN,
whereas MX1 and MX2 are (Figure S5B). To test whether
SUN2 was required for the CypA restriction, we generated
Sun2/ mouse bone-marrow-derived DCs (BMDCs) (Fig-
ure S5C) (Lei et al., 2009). In WT BMDCs, the infectivity of
HIVac-1 lentivector was reduced compared to HIV-1 WT lenti-
vector, and infectivity could be restored by CsA treatment, vali-
dating that the CypA-mediated restriction of HIVac is conserved
in mouse cells (Figures 5B, 5C, and S5D). Strikingly, in Sun2/
BMDCs, infectivity of HIVac-1 lentivector was largely rescued
(Figures 5B, 5C, and S5D). Furthermore, we found that viral
reverse transcription products of HIVac-1 lentivector were
similar between WT and Sun2/ cells, while 2LTR circles and
integrated viral DNA were reduced in WT cells and increased
in Sun2/ cells, in a fashion similar to the one observed with
CsA treatment of WT cells (Figure 5D). Thus, SUN2 is an
AB
Figure 4. Role of KnownCapsid-Associated
Factors in the Restriction
(A) GFP expression in PMA-differentiated THP-1
cells transduced with a control shRNA against
LacZ or individual shRNA against TNPO3, CPSF6,
NUP153, RANBP2, MX2, 48 hr after infection with
HIV-1WT, HIVac-1, HIV-2 WT, and HIVac-2 (n = 4,
paired t test, **p < 0.01, ***p < 0.001, bar indicates
mean). Virus inoculum volume is indicated.
(B) GFP expression in THP-1 cells transduced with
a control shRNA against LacZ or two individual
shRNA against TRIM5, 48 hr after infection with
HIV-1WT, HIVac-1, HIV-2 WT, and HIVac-2. As
sensitive control, THP-1 cells were infected with
MLV viruses RV(CL10A1) (TRIM5a resistant) and
RV(CIG3N) (TRIM5a sensitive) encoding GFP and
pseudotyped with VSV-G (n = 4, paired t test, **p <
0.01, ***p < 0.001; ns, not statistically significant;
bar, mean). Virus inoculum volume is indicated.
See also Figure S4.essential host factor for the CypA-mediated restriction of HIVac
capsids at nuclear import.
Effect of SUN2 on CypA-Dependent HIV Infection in
HeLa Cells
Next, we sought to extend the role of SUN2 to other activities of
CypA in HIV infection. We generated HeLa cells stably overex-
pressing SUN2 (Figure S5E). SUN2 inhibited the infection of
HIV-1 and HIV-2, confirming its antiviral activity when overex-
pressed (Figure 5E) (Schoggins et al., 2011). In HeLa cells, as
expected, HIV-1 WT and HIV-1 P90A are independent of CypA,
while HIV-1 N74D depends on CypA for infection (Figure 5E).
Overexpression of SUN2 inhibited HIV-1 N74D infection, and
CsA treatment did not reduce infectivity further, indicating that
SUN2 overexpression functions in the same pathway as CypA
in thismodel (Figure 5E). In these cells, whichwere used for infec-
tions,wealsoobserved thatSUN2overexpression leads tonuclei
that are ruffled and less circular, supporting the notion that an
optimal nuclear envelope structure is required for HIV infection
through SUN2 (Figures 5F–5H).
Role of SUN2 in Primary CD4+ Target Cells
Finally, we examined the contribution of endogenous SUN2 to
HIV-1 WT and HIV-2 WT infection in primary CD4+ targets and
THP-1 cells. In MDDCs, SUN2 knockdown reduced infection
by HIV-1 and HIV-2 (Figures 6A and 6B). Although dendritic cells
are physiologically relevant target cells for the immune response
to the virus, the bulk of viremia in patients is produced by CD4+
T lymphocytes. Depletion of SUN2 in primary activated human
CD4+ T cells reduced HIV-1 and HIV-2 infectivity similarly to
MDDCs (Figures 6C and 6D). SUN2-depleted cells showedCesimilar viability as compared to control
cells (Figures S6A and S6B). Depletion
of SUN2 also reduced accumulation of
HIV-1 over time using a replication-
competent virus (Figures 6E, 6F, S6C,
and S6D). In contrast to knockout mouse
BMDCs, transient depletion of SUN2 inhuman MDDCs, CD4+ T cells, and THP-1 cells was not sufficient
to rescue HIVac-1 or HIVac-2 infectivity (Figures 6C and S6E–
S6G). To determine the contribution of SUN2 to the role of
CypA during HIV-1 WT infection, we used the non-immunosup-
pressive CypA inhibitor, CBS1, in CD4+ T cells (Figure S6H).
SUN2 depletion or inhibition of CypA both reduced HIV-1 and
HIV-2 infectivity in CD4+ T cells (Figures 6C, 6G, and 6H). Impor-
tantly, combining CypA inhibition with SUN2 depletion did not
lead to additive inhibition (Figures 6G and 6H). Similar results
were obtained in THP-1 cells (Figure S6I). While the CypA inhib-
itor reduced viral RT cDNA levels in control cells, this effect of the
CypA inhibitor was lost in SUN2-depleted cells (Figure S6J).
Interestingly, CypA inhibition or SUN2 depletion did not reduce
the level of integrated DNA at a detectable level in CD4+ T cells
(Figure S6J). Thus, in primary CD4+ T cells, SUN2 is an essential
host factor for the positive effects of CypA on reverse transcrip-
tion and infectivity.
DISCUSSION
Here, we show that CypA mediates a conserved restriction
against a family of capsid mutants in HIV-1, HIV-2, and SIVmac,
and we leverage this phenotype to identify SUN2 as an essential
host factor in mediating the activities of CypA on HIV-1WT infec-
tion in primary CD4+ T cells.
The restriction applies to capsid mutants in HIV-1, HIV-2, and
SIVmac and has been consistently observed in primary cells and
cell lines of human, macaque, and mouse origin. The capsid
mutant family is exemplified by the HIVac-2 mutant, which
shows a strikingly enhanced affinity for CypA as compared to
HIV-2 and is dependent on CypA for inhibition of infection.ll Reports 15, 879–892, April 26, 2016 885
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HIVac-1, an analogous mutant in the CypA-binding loop, is also
restricted and dependent on CypA for inhibition, even though the
enhanced affinity is less striking (Lahaye et al., 2013). Impor-
tantly, themutant viruses display normal capsids at the structural
level (Lahaye et al., 2013) and proceed normally through RT,
unlike other CypA-binding mutants such as G89V and P90A
(Braaten et al., 1996), indicating that inhibition of their infectivity
does not result from gross structural defects. As expected, viral
mutants with a strong susceptibility to CypA-mediated restric-
tion are rapidly counter-selected in nature: HIV-1 WT escapes
this antiviral mechanism and genetic alteration in the virus is
required to reveal it, in accordance with the principle of restric-
tion factors (Malim and Bieniasz, 2012). Interestingly, our results
show that HIV-2 is slightly restricted by CypA, indicating that
it has not acquired a complete resistance to this antiviral
mechanism.
The restriction of HIVac capsids occurs after reverse tran-
scription and before nuclear import. We propose that the
acquisition of the ability of lentiviruses to enter the nucleus of
non-dividing cells (Goldstone et al., 2010; Lin and Emerman,
2006) offered an opportunity for co-evolution of a host defense
mechanism that inhibits lentiviral nuclear import, which can be
revealed by the family of capsid mutants described herein.
The combined observations that HIVac capsids are inhibited
at nuclear import and that the nuclear envelope protein SUN2
acts as an antiviral factor in HIV infection when overexpressed
prompted us to examine whether SUN2 could play a role in the
restriction of HIVac capsids. We show that Sun2 deficiency in
knockout mouse cells rescues infectivity of HIVac lentivectors.
Even though mouse cells are not natural targets of lentiviruses,
the restriction mediated by CypA was conserved and the rescue
of HIVac infectivity in Sun2 knockout cells thus provides a
compelling genetic demonstration. Prior to this work, HIV-1
capsid mutants A92E and G94D were selected in the presence
of CsA and became dependent on CypA inhibition for replication
(Aberham et al., 1996). This led to the hypothesis that a cell-type-
specific restriction factor inhibits HIV-1 infection after reverse
transcription but before nuclear import. However, unlike the
HIVac capsid mutants, A92E and G94D are generally not depen-
dent on CsA in other cell types (De Iaco and Luban, 2014; Qi
et al., 2008; Yin et al., 1998), and evidence for the existence of
a restriction factor is limited to a very narrow range of cell linesFigure 5. SUN2 Is Essential for the CypA Restriction of HIVac Capsid
(A) Quantification of late RT, 2LTR circles, and integrated viral cDNA products 24
(2 mM) or AZT (25 mM) (n = 3; paired t test on log-transformed data, ***p < 0.001,
(B) GFP expression in CD11c+ BMDCs (WT or Sun2/) 72 hr after infection wit
psPAX2 or psPAX2 HIVac mutant and treated or not with CsA (2 mM) (n = 4; repr
(C) Dose response of GFP expression as in (B) (n = 4, line indicates mean). Virus
(D) Quantification of late RT, 2LTR circles, and integrated viral cDNA products 48 h
(n = 2; bar, mean).
(E) Titer of indicated viruses on control HeLa cells (Empty vector) or SUN2-overexp
paired RM ANOVA one-way test, *p < 0.05, ***p < 0.001, ****p < 0.0001; ns, not
(F) Maximum intensity z-axis projection of the SUN2 staining (anti-SUN2) in cont
Scale bar, 5 mm.
(G) Principle of the confocal image acquisition shown in (H).
(H)DAPI andSUN2staining (total anti-SUN2oroverexpressedV5-taggedSUN2) in c
The three panels (top, middle, and bottom) correspond to the description in Figure
See also Figure S5.(De Iaco and Luban, 2014; Song and Aiken, 2007). Moreover, it
is, so far, not apparent in primary CD4+ target cells of the virus
(Qi et al., 2008). CypA was also suggested to modulate HIV-1 re-
striction specifically in owl monkey cells (Towers et al., 2003), but
this was later found to stem from a TRIM5-CypA fusion protein in
this species (Nisole et al., 2004; Sayah et al., 2004). In contrast,
our results establish a conserved CypA-dependent restriction
that is active in primary CD4+ target cells, indicating a weakness
point in the viral cycle. Unexpectedly though, SUN2 knockdown
in human cells did not rescue HIVac capsids, as opposed to
knockout murine BMDCs. We envision three possibilities: (1)
transient knockdown of SUN2 differentially impacts the CypA-
dependent restriction in cells as compared to the constitutive
knockout that may be developmentally compensated; (2) there
are underlying species differences between human and mouse
SUN2; (3) there are underlying cell-type differences betweenmu-
rine bone-marrow-derived-DCs and human immune cells. We
generated CRISPR/Cas9 knockouts of SUN2 in THP-1 cells,
but observed an unexpected loss of CypA dependency on
HIV-1 infection in this experiment, questioning the applicability
of this approach (data not shown). It will be important to develop
methods to further manipulate SUN2 expression in HIV target
cells.
Looking at known capsid-associated factors, we show that
depletion of MX2, TNPO3, CPSF6, NUP153, RANBP2, or TRIM5
do not rescue HIVac-1 or HIVac-2 infectivity. While we cannot
exclude that the host factor knockdowns were not sufficient, our
inability to detect even a partial rescue, when control infections
with wild-type virus or MLV were affected, strongly suggests
that none of these factors contributed to the CypA-dependent
restriction. Unexpectedly, MX2 was constitutively expressed in
THP-1 cells in the absence of type I IFN, and its depletion reduced
HIV-1 and HIV-2 infection in PMA-treated cells, suggesting that
MX2 may not be antiviral in differentiated myeloid immune cells
in the absence of type I IFN. In contrast, the N74D and N73Dmu-
tations, which lie in the binding pocket of CPSF6 and NUP153
(Matreyek et al., 2013; Price et al., 2012), rescued HIVac-1 and
HIVac-2 infection from CypA restriction. Since CPSF6 or
NUP153 knockdown did not lead to similar rescue, it is possible
that another host factor binds the same capsid region, or that
the mutation causes structural consequences further away from
the CPSF6 and NUP153 binding pocket. It will be interesting tohr after infection of DCs with HIV-2 WT or HIVac-2. Cells were treated with CsA
**p < 0.01; ns, not statistically significant; bar, mean).
h pTRIP-SFFV-GFP lentivectors, pseudotyped with VSV-G, encapsidated by
esentative data for one donor are shown).
inoculum volume is indicated.
r after infection of BMDCs (WT or Sun2/). Cells were treated with CsA (2 mM)
ressing HeLa cells (SUN2-V5), in the presence or absence of CsA (2 mM) (n = 5,
statistically significant; bar, mean ± SEM).
rol HeLa cells (Empty vector) or SUN2-overexpressing HeLa cells (SUN2-V5).
ontrolHeLacells (Emptyvector) orSUN2-overexpressingHeLacells (SUN2-V5).
5G (n = 3, representative data for one experiment are shown). Scale bar, 5 mm.
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Figure 6. SUN2 Is an Essential Host Factor of HIV-1 and HIV-2 in Primary CD4+ Target Cells
(A) Western blot analysis of SUN2 and actin expression at the time of infection (day 4) in MDDCs that were transduced at day 0 with shRNA vectors against SUN2
(shRNA#4 or shRNA#5) or a shRNA control vector (LacZ shRNA).
(B) MDDCs as in (A) infected at day 4 with HIV-1 WT or HIV-2 WT. Proportion of GFP-positive cells after 48 hr of infection (n = 4, paired RM ANOVA one-way test,
**p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not statistically significant; LacZ shRNA versus SUN2 shRNA#4 [blue] or SUN2 shRNA#4 [red]; line, mean). Virus
inoculum volume is indicated.
(C) Western blot analysis of SUN2 and actin expression at the time of infection (day 7) in activated CD4+ T cells that were transduced at day 1 with shRNA vectors
against SUN2 (shRNA#4 or shRNA#5) or a shRNA control vector (LacZ shRNA).
(D) Activated CD4+ T cells as in (C) infected at day 7 with HIV-1 WT or HIV-2 WT. Proportion of GFP-positive cells after 48 hr of infection (n = 4, paired RM ANOVA
one-way test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, LacZ shRNA versus SUN2 shRNA#4 [blue] or SUN2 shRNA#4 [red]; line, mean). Virus inoculum
volume is indicated.
(legend continued on next page)
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evaluatewhetherdepletionof these factors in thecontext ofSUN2
overexpression or depletion differentially impacts infection with
HIV-1 WT and capsid mutants.
The restriction of HIVac capsids at nuclear import and their
rescue in SUN2 knockout cells is an artificial situation that we
leveraged to more broadly understand the natural mechanisms
of CypA activities during HIV infection. We provide evidence
in two additional models of CypA activities that SUN2 is a key
host factor. First, we examined HeLa cells, in which CypA has
no effect on HIV-1WT infectivity but promotes HIV-1 N74D infec-
tivity. Accordingly, SUN2 overexpression in HeLa cells cancels
the positive effect of CypA on HIV-1 N74D infectivity. Optimal
SUN2 levels are thus required for CypA activity on HIV infection
in HeLa cells. This is unlikely to be a non-specific effect of over-
expression, because it was selective for HIV-1 N74D, and SUN2
overexpression was previously found to have no impact on
several other viruses (Schoggins et al., 2011). Second, we exam-
ined the role of SUN2 inmediating the positive effects of CypA on
HIV infectivity in primary CD4+ T cells and MDDCs. Using two
distinct shRNAs targeting SUN2, we showed that SUN2 is an
essential host factor of HIV-1 and HIV-2 infection. Furthermore,
in CD4+ T cells, SUN2 depletion was not additive with CypA in-
hibition of HIV-1 infectivity, and it abrogated the CypA depen-
dence of HIV-1 reverse transcription. Interestingly, SUN2 deple-
tion had a strong effect on HIV-1 infectivity but little effect on viral
late RT products and integrated cDNA levels at the time point
examined. This suggests the possibility that SUN2 may regulate
the dynamics of the early steps of replication, integration sites, or
viral transcription to impact HIV infectivity, and these possibilities
warrant further study. Overall, our results show that, while SUN2
and CypA can mediate a potent restriction of HIVac capsids,
HIV-1 WT has evolved to exploit SUN2 and CypA instead of
being susceptible to their restriction. Furthermore, SUN2 is
required for both HIV-1 and HIV-2 in CD4+ cells, indicating that
SUN2 is an essential HIV-associated factor, including but not
limited to CypA activities.
The ability of artificial SUN2 overexpression to inhibit HIV
was previously reported in several transformed cell lines and
in MDDCs (Donahue et al., 2016; Schoggins et al., 2011). We
now show that endogenous SUN2 mediates CypA activities on
infection and that endogenous SUN2 is essential for infection
in relevant primary CD4+ T cells.
It is noteworthy that both SUN2 overexpression and deple-
tion reduce HIV-1 WT infection. This suggests a non-linear
biphasic response (i.e., hormesis) with the endogenous level
of SUN2 being the optimal level for infection. SUN2 levels in
various target cells or tissue environments may have been a
driving force in selecting an optimal level of CypA affinity in
lentiviral capsids. Future studies on SUN2 in HIV infection will(E) Analysis of HIV-1 replication in SUN2-depleted CD4+ T cells over time, outlin
(F) HIV-1 p24 concentration at days 5, 6, 7, and 8 in SUN2-depleted CD4+ T cells
shown; see Figure S6 for four additional donors).
(G) GFP expression in CD4+ T cells 48 hr after infection with HIV-1 WT, encoding
CBS1 (60 mM) (n = 8; representative data for one donor are shown).
(H) Titers of HIV-1 WT and HIV-2 WT calculated from infections with serial dilution
HIV-2 viruses n = 4, paired RM ANOVA one-way test, ****p < 0.0001, ***p < 0.00
See also Figure S6.require experimental setups that allow a precise control over-
expression levels. In HeLa cells, SUN2 overexpression inhibits
HIV-1 infection and simultaneously leads to deformation of
nuclei that become ruffled and less circular, pointing to a
tempting link between nuclear envelope architecture and HIV
infectivity. SUN2 does not associate with nuclear pores but
connects the nucleoskeleton with the cytoskeleton through ne-
sprins (Liu et al., 2007; Tzur et al., 2006), and it will be important
to examine the contribution of these other factors to the effects
of CypA during HIV infection.
Since SUN2 is a protein of the inner nuclear membrane of the
nuclear envelope, it could potentially interact directly with the nu-
clear fraction of the viral capsid (Chin et al., 2015). The interaction
between the capsid and SUN2 could alternatively be indirect,
such as through nuclear lamins or nesprins. SUN2 could thus
contribute to viral uncoating in the cytosol, to virus docking on
the nuclear pore, to its transport through the nuclear pore, and
to its targeting to specific regions of chromatin. All of these pos-
sibilities have been shown to depend on binding of the HIV-1
capsid to CypA (Campbell and Hope, 2015).
Overall, our results establish that CypA has a conserved ability
to restrict lentiviral infection and that SUN2 is a key host factor in
mediating both positive and negative activities of CypA on infec-
tion. This enables us to unravel the detailed molecular mecha-
nisms of CypA and SUN2 in the context of HIV infection and
extends our understanding of the desirable antiviral defenses
that are normally bypassed by HIV-1.
EXPERIMENTAL PROCEDURES
Constructs
The HIV-1 WT construct was NL4-3 DvifDvprDvpuDenvDnef encoding GFP
or tagRFP in nef, and the HIV-2 WT construct was ROD9 DenvDnef encoding
GFP in nef as previously described (Manel et al., 2010). SIVmac239 WT
construct was SIVmac239 DenvDnef encoding GFP in Nef. Mutants HIV-1
N74D, HIV-1 V86I-IAP91LPA-M96L (HIVac-1), HIVac-1 N73D, HIV-2 N73D,
HIV-2 P86HA (HIVac-2), P86RA, P86QA, P86AA, P86AM, P86HV, P86PI,
HIvac-2 N73D, SIVmac239 QPAPQQ85IHAGPLPA, and psPAX2 variant
(HIVac-1 mutation) were generated by overlapping PCR mutagenesis. In all
final constructs, the entire DNA fragments originating from the PCR and
encompassing the restriction sites used for cloning were fully verified by
sequencing. Plasmid DNA was purified using with the low endotoxin HiPure
plasmid kit (Invitrogen). Recombinant plasmid DNA did not induce den-
dritic cell maturation, and viral-producing cells were washed after DNA
transfection.
Cells
GHOST (GHOST X4R5), 293FT, and HeLa cells were cultured in DMEM, 10%
fetal bovine serum (FBS) (Gibco), and penicillin-streptomycin (Gibco). THP-1
and Jurkat cells were cultured in RPMI medium, 10% FBS (Gibco), and peni-
cillin-streptomycin (Gibco), and THP-1 cells were differentiated with 30 ng/ml
(50 nM) of PMA for 16 hr. CD4+ T lymphocytes and CD14+ monocytes weree of the experiment.
following infection by replication-competent HIV-1 as in (E) (n = 6; two donors
GFP in Nef and pseudotyped with VSV-G and in the presence or absence of
s of viruses as in (G), in the presence or absence of CBS1 (60 mM) (n = 6, except
1; ns, not statistically significant).
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isolated from adult human blood. DCs were generated from blood CD14+
monocytes using granulocyte macrophage colony-stimulating factor (GM-
CSF) and interleukin-4 (IL-4).
Virus Production
Viral particles were produced by transfection of 293FT cells in 6-well plates
with 3 mg DNA and 8 ml TransIT-293 (Mirus Bio) per well. One day after trans-
fection, media was removed, cells were washed once, and fresh media was
added. Viral supernatants were harvested 1 day later, filtered at 0.45 mM,
used fresh or aliquoted, and frozen at 80C. Viral titers were measured on
GHOST cells titration as previously described (Manel et al., 2010). RT activity
in viral supernatants was measured using the SG-PERT assay (Pizzato et al.,
2009) using M-MuLV RT (Finnzyme) as a standard. Viral supernatants did
not induce dendritic cell activation in the absence infection.
Infections
At day 4 of MDDC differentiation (or day 7 for BMDCs), cells were
harvested, counted, and resuspended in fresh medium at a concentration
of one million per ml with 5 mg/ml polybrene, GM-CSF, and IL-4 (or in
BMDCs DC medium); 100 ml were aliquoted in round-bottomed 96-well
plates, and virus dilutions and treatments were added. 48 hr after infec-
tion, cell-culture supernatants were harvested and UV-irradiated to inac-
tivate free virus. For CD4+ T cells infection, activated cells were har-
vested, counted, and resuspended in fresh medium at a concentration of
0.25 million per ml with 8 mg/ml protamine. 100 ml of cells was aliquoted
in round-bottomed 96-well plates, and virus dilutions and treatments
were added. 48 hr after infection, cells were fixed and analyzed. HeLa
were infected similarly to GHOST cells as previously described (Manel
et al., 2010) with 8 mg/ml protamine.
Statistics
Statistical analyses were performed in Prism (GraphPad). The paired t test or
paired repeated measures (RM) ANOVA one-way test were used, unless indi-
cated otherwise in figure legends. In figures, *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001; ns, not significant.
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